Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass management will host a conference call at 8:00 am ET (1:00pm UK)

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter 2024 ending December 31, 2024, and provide an update on recent developments, on February 27 th , 2025.

Compass management will host a conference call at 8:00 am ET (1:00pm UK) on February 27, 2025. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin.

A live webcast of the call will be available on the Compass Pathways website at: Fourth Quarter 2024 Financial Results

The webcast will also be available on the Investors section of Compass Pathways website. The webcast will be archived for 30 days.

About Compass Pathways

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are living with mental health challenges and who are not helped by existing standards of care. We are pioneering the development of a new model of psilocybin treatment, in which our proprietary formulation of synthesized psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD).

We have commenced a phase 3 clinical program of COMP360 psilocybin treatment in TRD, the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted. Previously, we completed a phase 2b study with top line data showing a statistically significant (p

Compass is headquartered in London, UK, with offices in New York and San Francisco in the US. Our vision is a world of mental wellbeing.

Enquiries
Media: media@compasspathways.com
Investors: Stephen Schultz, stephen.schultz@compasspathways.com , +1 401 290 7324

News Provided by Business Wire via QuoteMedia

CMPS:US
The Conversation (0)
Dried mushrooms and capsules aligned on a light surface.

Psychedelics Market Update: H1 2025 in Review

The market for psychedelic drugs is emerging as a strategic investment opportunity in healthcare, with forecasts generally placing its value at around US$6.4 billion in 2025. This burgeoning sector is set for robust, double-digit compound annual growth, significantly driven by North America,... Keep Reading...
Glowing mushrooms with colorful graphs in the background on a dark surface.

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry. However, the sector is seeing a resurgence of optimism in 2025 on the back of various... Keep Reading...
"2023 year-end review" text overlaid on image of psychedelic mushrooms.

Psychedelics Market 2023 Year-End Review

The psychedelics industry is maturing after the investment boom of 2020 and 2021, and patient long-term investors looking for opportunities to diversify their portfolios have options when it comes to exposure. As clinical trials and research continue to demonstrate the potential benefits of... Keep Reading...
Glowing pyschedelic mushrooms.

How to Invest in Psychedelics

Market participants are wondering how to invest in psychedelics as the opportunity attached to these drugs grows.Promising research associated with psychedelic medicine shows the potential for these products to treat mental health issues and even addiction to opioids. “(Psychedelic)-assisted... Keep Reading...
A colorful brain illustrating brain on pyschedelics.

Psychedelics Stocks to Watch

The small-cap market has been invaded by a flurry of psychedelics stocks to watch thanks to new company launches. Investors now have a variety of options for taking a run in the shroom stocks space.In an effort to expand the capabilities of the medical field, companies are starting to... Keep Reading...
Albert Labs

Albert Labs Announces Expansion of Drug Discovery and a Promising Pipeline

Albert Labs International Corp. ([CSE: ABRT], the "Company" or "Albert Labs"), a fully-integrated biopharmaceutical drug discovery company bringing innovative medicines to patients with unmet mental health needs, is pleased to announce the expansion of its drug discovery pipeline, broadening the... Keep Reading...

Interactive Chart

Latest Press Releases

Related News